



Cystic Fibrosis (CF)

Muna Kilani, MD

← عشان هيك في كتي دراسات عليه و في Foundations خاصة
لعلاج مرضي ال CF ، و بشكل عام معروف كتي عن هاد المرض

- Among the most common life shortening genetic illnesses, median survival is ~~41~~₄₇ years
- Chronic, progressive obstructive lung disease.
- Associated with pancreatic insufficiency, liver disease, CF related diabetes militus.
- There is no currently no cure for CF

Epidemiology


- 30,000 cases in North America.
- Incidence 1:3200 in whites, 1:15000 in people of african decent. → More common in whites (caucasians)
- Incidence of CF in Jordan ???
 ↳ In Jordan we have about 200-250 cases
 * In Jordan we have a problem in diagnosing CF
 so a lot of cases are misdiagnosed

Pathogenesis

- The disease is caused by a genetic mutation on chromosome 7q31.2, which codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
 ↳ This protein is present on cells other than epithelial cells,
- CFTR is an apical epithelial chloride channel. but in CF the main problem is with those on epithelial cells.
- 1900 mutations have been identified, all categorized into 6 distinct classes.

* متى مريض نختار

- Class 1: Lack of protein production
→ The most common mutation
- Class 2: Defect in protein trafficking with degradation in endoplasmic reticulum → ما بطلع على apical membrane
- Class 3: Defective regulation of CFTR
- Class 4: Reduced chloride transport through the apical membrane
- Class 5: Splicing defect with reduced production of CFTR
- Class 6: Decreased CFTR stability
← بطلع و بعدين يرجع و بيسره degradation



wt-CFTR	I	II	III	IV	V	VI
	No protein	No traffic	No Function	Less Function	Less Protein	Less Stable

G542X (a)	R1066C	G551D	R117H	A455E	c.120del23
394delTT (a)	A561E	S549R	R334W	3272-26A>G	rF508del
1717-1G>A (b)	F508del	G1349D	3849 + 10 kb C>T		

Most Common

These are associated w/ a better prognosis

الحالات اللي
من هاد النوع قليل

* صار مريض نعرف نوع ال mutation اللي عند المريض ، لأنه صار في medications معينة حسب ال mutation

- Most common mutation delta 508, it is a class 2 mutation, [70% have one gene, 50% have 2 genes.] → من كل مريض ال CF
- G551D is a class 3 mutation, that is targeted by Ivacaftor.

- 2 mutations are needed for the disease
- Classes 1-3 are associated with early onset of disease, and pancreatic insufficiency *
- Classes 4-5, are associated with later onset lung disease, and pancreatic sufficiency *



* مهم نعرف انه مش كل مريض ال CF عنده Pancreatic Insufficiency

* about 15-20% have pancreatic sufficiency

* بشكل عام ال CF مش كيت عا بالعدوت ، بس كيت به دخل بال DDx

CFTR: A cAMP-Regulated Chloride Channel

The net ion flow across normal and cystic fibrosis cell



Pathophysiology

- Lungs: Mucus plugging==inflammation, chronic infection, small airway obstruction, bronchiectasis
- Exocrine pancreas, intestines and liver: viciid secretions==Pancreatic insufficiency, intestinal obstruction,cholestasis.
- Other systems: Pansinusitis, nasal polyps and infertility, increased salt excretion in the sweat.

Cystic Fibrosis → differential Dx بالـ بدني سني بالـ Dx differential

Diagnosis

- Cystic Fibrosis Foundation diagnostic criteria:
 - The presence of 1 or more phenotypic symptoms of CF like, recurrent sinopulmonary disease, nutritional of gastrointestinal symptoms, or absence of vas deference.
 - OR
 - Positive family history of CF in a sibling
 - OR → It is found that early detection and management of the disease can ↑ the life expectancy of the pts.
 - Positive newborn screen, can ↑ the life expectancy of the pts.
 - with evidence of chloride transport abnormalitis
 - Abnormal sweat test on 2 separate occasions
 - Abnormal nasal epithelial cell potential
 - The presence of 2 known CF causing mutations on genetic testing

* ملاحظة * بشكل عام عشان أعمل screening لأي مرض لازم
أكون بقرار أعمل اشي (أعالجه) أو أسيق من فكرة اني اكشفه
(يكون preventable)

→ Newborn screening includes

- Hypothyroidism
- galactosemia
- Phenylketonuria

* The sweat test measures the concentration of Chloride that is excreted in sweat. It is used to screen for CF.
 Due to defective chloride channels (CFTR), the concentration of the Cl^- in sweat is elevated in individuals w/ CF

The gold standard for diagnosis of CF remains the pilocarpine iontophoresis sweat test developed by Gibson and Cooke in 1959

← هاد التست قديم و صعب يتعمل (ظنواة كثيرة)

> 60
 عنو CF
 ✓

Interpretation of Sweat Chloride Concentration	
Group Interpretation	
Infants age 0-6 months	
Sweat chloride concentration (mEq/L)	
0-29	CF is unlikely
30-59	Intermediate
→ 60	Indicative of CF
Infants age >6 months, children, and adults	
Sweat chloride concentration (mEq/L)	
0-39	CF is unlikely
40-59	Intermediate
→ 60	Indicative of CF

Note: Read about the method of how this test is done on Wikipedia.

المشكلة بالذات انه هاد التست نتايجها من دقيقة لأنه ما بتلغوا

ال chloride level ، بتلغوا ال NaCl .

Diagnosis

- False positive sweat Cl:
 - Eczema, Ectodermal dysplasia, malnutrition, congenital adrenal hyperplasia, Adrenal insufficiency, hypothyroidism.
- False negative sweat Cl:
 - Dilution, edema, inadequate sweat.

Diagnosis

- Abnormal nasal potential difference measurement. (Absence of voltage after pilocarpine administration).

- * • Fecal elastase to measure exocrine pancreatic junction.

To determine if there is

↳ Pancreatic sufficiency
↳ Pancreatic insufficiency

- Genetic testing:

- usually look for 30-96 mutations.

- Complete sequencing of the CFTR gene is available for atypical cases

- List of clinical manifestations associated with the individual CFTR mutations are available on www.cftr2.org

طارد السمات
من ج ١٠
من موجود بالمرن

Diagnosis

- Newborn screening was implemented in all states in 2010
- Newborn screening was associated with improved nutritional status, and lung function at age 6.
- It has 90% sensitivity but low specificity.
- Immunoreactive trypsinogen is measured in the newborns blood.
 - a positive test needs referral to a pulmonologist , and the performance of a sweat test.
- False negative newborn screening can happen especially in infants with meconium ileus.

Clinical Manifestations

- Recurrent sinopulmonary infection
 ← مع الزمن يصبى عندهم Respiratory failure و bronchiectasis
 و بعد من يحتاجوا lung transplant
- Stetorrhea (due to malabsorption)
- Failure to thrive. (The triad of symptoms)

Clinical Manifestations by age

- Hyperechoic bowel of fetal US, is suggestive of CF
- ✱ • Delayed meconium passage, meconium plugging and meconium ileus, are present in 15-20% of infants with CF.
- Due to high protein in meconium
- inspissation of meconium is bowel leading to intestinal obstruction... usually needs surgical removal
- Rectal prolapse
- Seen in patients 6m—3years
- Due to malnutrition, elimination of large stools

فأي طفل يصبى
 عنده شك من علاقه
 screening for CF

Clinical Manifestations

- Less frequent manifestations in infancy
- Salt depletion syndrome, results in hyponatremic, hypokalemic, hypochloremic metabolic alkalosis.
- ★ • Prolonged neonatal jaundice from intrahepatic biliary stasis, and extra hepatic biliary obstruction.
- Edema and hypoproteinemia from malabsorption
- Hemorrhagic disease of the newborn from Vit K deficiency.

طلي العنكة
بشال في كيت

(In general CF pts have deficiency in fat absorbable vitamins)

↳ A/K/E/D

Clinical Manifestations

- In older children, adolescents and adults.
- Recurrent lung infection
- Poorly controlled asthma
- Bronchiectasis
- Recurrent sinusitis and nasal polyps
- Hemoptysis, pneumothorax
- Respiratory failure

Clinical Manifestations

- Malabsorption
- DIOS...Distal Intestinal obstruction syndrome
- Rectal prolapse
- Liver disease
- Infertility absent vas deference

Management

- The aim of management is to
 - Maintain optimal lung function
 - Antibiotics
 - Lung clearance
 - Anti inflammatory medications
 - Maintain optimal nutritional status

المفروض مرضي لا CF
يكون لهم centers
خاصة فيهم يتعالجوا
فيها (مؤيد بالبيانات
و المستشفيات العادية)
حتى يحصل على
الرعاية الكافية التي
محتاجها من ناس
مختصة بهذا
الموضوع

Management

- In the US cystic fibrosis care is provided at CF foundation accredited centers with a multi disciplinary team approach.

Cystic Fibrosis Foundation's Pulmonary Clinical Practice Guidelines Committee developed recommendations that were based on a systematic review of the literature and assessment of the available evidence based on an established grading scale. These guidelines were updated in 2013


ما تدقق في
عليهم

Management

- Chronic airway infection
 - surveillance cultures; pseudomonas, staph aureus, atypical mycobacterial infections, fungal infections
 - First evidence of pseudomona colonization is usually treated with inhaled tobramycin
 - Patients with chronic pseudomonas infection, can benefit from inhaled antibiotics every other month
 - Acute exacerbations are treated with IV antibiotics usually double coverage for pseudomonas and depending on the sensitivities obtained by sputum culture.

CF pts in childhood → The most common bacteria is Staph aureus
with age → Pseudomonas

*** Important**



عشان هيل موصي ال CF مش لازم

ينخطوا مع بعض، كل واحد لازم يعزوا و يعالجوا لحاله
عشان ما يعزوا بعض

Management

- Airway clearance
- Percussion, postural drainage, active cycle breathing, positive expiratory pressure, high frequency chest wall oscillation.
- Usually combined with mucus alternating agents like DNase, and hypertonic saline 7%.
- Usually done twice daily and increased frequency with acute infections.

مش موجودين بالزيت

- Disease-Modifying Therapies
 - Ivacaftor is an oral pharmacologic potentiator
 - Activates defective CFTR in patients with class 3 mutation G511D
 - Approved for patients with at least one G511D mutation

- Chronic airway inflammation
 - Ibuprofen: high doses (blood levels of 50-100microgm/ml) have been associated with decrease neutrophil migration and decreased inflammation
 - Azithromycin: used 3 times/week, improves lung function and lessens exacerbations
 - Steroids: Should not be used routinely

Management

- Pancreatic enzyme replacement therapy
 - Pancreatic enzymes must be taken with every meal and snack
 - The dose is 2000-2500u/kg of lipase/meal
 - Too high of a dose causes fibrosing colonopathy
- Fat soluble vitamins replacement therapy
 - AKED vitamins

Management

- Management of the complications
 - Pulmonary exacerbation: worsening cough, shortness of breath, fatigue or weight loss, decrease in lung functions
 - Treatment is with antibiotics, oral, IV or inhaled depending on culture results and sensitivities.

Management

- Hemoptysis 9% of patients:
 - usually from bronchial arteries, in advance disease
 - treatment is antibiotics for mild to moderate, 5-250ml
 - Bronchial artery embolization or lung resection for sever bleeding
- Pneumothorax in 3.4% of patients
 - If small to moderate management depends on degree of respiratory compromise
 - If large a chest tube needs to be inserted
 - if large and recurrent, chemical or surgical pleurodesis

Management

- Chronic rhinosinusitis and nasal polyps
 - Medical therapy with inhaled steroids, saline rinses
 - surgery, functional endoscopic sinus surgery.
- DIOS
 - Viciid fecal matter obstructing distal intestines, risk factors include fat malabsorption secondary to insufficient enzyme replacement, dehydration, a history of meconium ileum
 - Treatment is hydration, and osmotic laxatives, in cases of complete obstruction gastrografen enema

Management

- CF liver disease
 - Patient get biliary fibrosis that leads to biliary cirrhosis and liver cirrhosis
 - Hepatomegaly, abnormal liver functions and abnormal liver US and and an abnormal liver biopsy
 - Treatment is ursodeoxycholic acid

Management

- Cystic Fibrosis Related Diabetes Mellitus *Type 1*
 - CFRD has been associated with decreased body mass index, lung functions and mortality
 - Early control improves outcome and mortality
 - Microvascular complications of DM can happen
 - Incidence increase 5% per year after 10 years of age, and 10% per year after 20 years of age
 - Recommended to perform a glucose tolerance test yearly after 1 year of age, HA1C is not recommended as it underestimates the glycemic load
 - Treatment is with Insulin, oral hypoglycemic agents are not recommended
 - Caloric restriction is not recommended, intake of carbohydrates is not discouraged.

Management

- CFTR modulator therapies
- Ivacaftor
- Ivacaftor and lumacaftor Orkambi

Table 1. Most common CFTR mutations causing CF in 2013

Mutation	Prevalence (%)
→ F508del	86.4 <i>Most Common</i>
One copy	39.9
Two copies	46.5
G542X	4.6
G551D	4.4

Abbreviations used: CFTR, cystic fibrosis transmembrane conductance regulator; CF, cystic fibrosis.

Management

- Lung transplantation
- 5 year survival about 70%

← عادة ال lung الجديدة يصير لها colonization بنفس
ال organisms التي كانت موجودة بال lung القديمة
و السبب لأنه هائي ال organisms رح تيجي من ال sinuses

- Questions???